Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.

about

Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.

Item

http://www.wikidata.org/entity/Q36094171

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@ast

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@en

type

Item

label

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@ast

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@en

prefLabel

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@ast

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@en

P1476

Treatment of breast cancer 2 ( ...... ARP) inhibitor: a case report.

@en

P2093

Brian McCaughan

http://www.w3.org/2001/XMLSchema#string

Charlotte R Lemech

http://www.w3.org/2001/XMLSchema#string

Melvin Chin

http://www.w3.org/2001/XMLSchema#string

Rachel Williams

http://www.w3.org/2001/XMLSchema#string

Stephen R Thompson

http://www.w3.org/2001/XMLSchema#string

P2860

A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Clinicopathological features and prognosis assessment of extranodal follicular dendritic cell sarcoma

Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Follicular dendritic cells as accessory cells.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized.

Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

P2888

s13104-016-2189-x

P304

386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S13104-016-2189-X

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029511688

http://www.w3.org/2001/XMLSchema#string

P698

27488020

http://www.w3.org/2001/XMLSchema#string

P932

4973114

http://www.w3.org/2001/XMLSchema#string